{"schema_version":"secwatch.filing_event.v1","accession":"0001723128-23-000006","form_type":"8-K","ticker":"AMRX","cik":"0001723128","company_name":"Amneal Pharmaceuticals, Inc.","filed_at":"2023-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.313468+00:00","generated_at":"2026-06-18T15:36:42.745811+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Amneal Q4 revenue $610M (+14% YoY), adj. EBITDA $154M; FY23 guidance $2.25-2.35B","bullets":["Q4 2022 net revenue $610M (+14% YoY); GAAP net loss $4M ($0.03 loss per share).","Q4 adjusted net income $71M, adjusted EBITDA $154M (+26% YoY), adjusted diluted EPS $0.23.","Full year 2022 net revenue $2.21B (+6% YoY); GAAP net loss $130M ($0.86 loss per share) including $263M Opana litigation charge.","Full year adjusted EBITDA $514M (+$2M YoY), adjusted diluted EPS $0.68.","2023 guidance: net revenue $2.25-2.35B, adjusted EBITDA $500-530M."],"urls":{"canonical":"https://secwatch.observer/filing/0001723128-23-000006","json":"https://secwatch.observer/filing/0001723128-23-000006.json","markdown":"https://secwatch.observer/filing/0001723128-23-000006.md","text":"https://secwatch.observer/filing/0001723128-23-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/amrx-20230302.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T15:36:42.745811+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"28aa33902192fcf7815758a59abbce3c4290f3d2","claim":"Amneal Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $610 million, net income $4 million, EPS $0.03. Guidance initiated.","evidence_excerpt":"Q4 2022 Net Revenue of $610 million; GAAP Net Loss of $4 million; Diluted Loss per Share of $0.03","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$610 million"},{"label":"Net income","value":"$4 million"},{"label":"EPS","value":"$0.03"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8e0aae7e20dad9e3b24a3db4219c08da7105885d","claim":"Amneal Pharmaceuticals, Inc. reported the year ended December 31, 2022 results: revenue $2.21 billion, net income $130 million, EPS $0.86. Guidance initiated.","evidence_excerpt":"Full Year 2022 Net Revenue of $2.21 billion; GAAP Net Loss of $130 million; Diluted Loss per Share of $0.86","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1723128/000172312823000006/0001723128-23-000006-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Revenue","value":"$2.21 billion"},{"label":"Net income","value":"$130 million"},{"label":"EPS","value":"$0.86"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}